Oriel Therapeutics, a developer of dry inhaler technology, has signed a contract for development of a therapy to threat cystic fibrosis.

However, Oriel said it cannot identify its partner for the project other than to say it is a “US-based biotechnology company”.

Oriel said the deal could be worth millions of dollars in licensing fees, achievement of milestone fees and royalties. Oriel said the contract also includes options for other therapeutic applications.
The therapy will be based on its dry power inhalation technology as well as compounds provided by the partner in the project.

Cystic fibrosis, a genetic disorder that affects the lungs and digestion, affects some 30,000 people in the US.

Oriel said the new therapy would be faster than traditional drug treatments with the new treatment requiring one inhalation.

“We believe that our technology has broad applicability across a wide range of powder formulations used to treat major pulmonary ailments including asthma, COPD and cystic fibrosis,” said Oriel CEO Paul Atkins, in a statement. “This agreement to develop a novel therapy for treating cystic fibrosis is an exciting endorsement of the technology and we are delighted with this relationship.”

Oriel’s technology is based on research done at the University of North Carolina at Chapel Hill.

Oriel: www.orieltherapeutics.com